Skip to main content
. 2021 Sep 25;53(3):436–448. doi: 10.3947/ic.2020.0126

Table 2. Showing baseline demographics and medical conditions in patients.

Demographics
Sample n 168
Ruxolitinib group sample size n (%) 46 (27.4%)
Standard of care group sample size n (%) 122 (72.6%)
Male n (%) 88 (52.4%)
Underlying medical conditions n (%)
Diabetes mellitus (%) 42 (25%)
Hypertension (%) 93 (55.4%)
Cardiovascular disease (%) 42 (25%)
Chronic lung disease (%) 37 (22.0%)
Current or previous smoker (%) 33 (19.6%)
Graft-versus-host disease 2 (1.2%)